Hecht Birgit
Med Monatsschr Pharm. 2010 Apr;33(4):120-30; quiz 131-2.
Orally disposable drugs for the treatment of multiple sclerosis have been research topics for long-term. Actually there are several drugs in clinical trial. Their mode of action differs among themselves and from established therapeutic agents. While cladribine acts as an antimetabolite and reduces lymphocytopoiesis, fingolimod influences circulation of lymphocytes. Fampridine alleviates symptoms by blocking potassium-channels. These and other drugs which are currently examined for oral administration are presented. The main focus is on the mode of action of these new drugs, in addition important results of clinical trials are summarized.
用于治疗多发性硬化症的口服一次性药物长期以来一直是研究课题。实际上，有几种药物正在进行临床试验。它们的作用方式彼此不同，也与已有的治疗药物不同。克拉屈滨作为一种抗代谢物，可减少淋巴细胞生成，而芬戈莫德则影响淋巴细胞的循环。氨吡啶通过阻断钾通道来缓解症状。本文介绍了这些以及目前正在研究口服给药的其他药物。主要重点是这些新药的作用方式，此外还总结了临床试验的重要结果。
